<ul>
<li>德康醫療股票：財報超預期和新市場準入推動看漲預期</li>
</ul>
<p>德康醫療公司（NASDAQ:DXCM - 免費報告）- 股票分析師在 7 月 30 日星期三發佈的報告中，上調了德康醫療 2028 財年的每股收益（EPS）預期。Leerink Partnrs 的分析師 M. Kratky 現在預計該醫療設備公司將實現每股收益 3.83 美元，高於之前的 3.82 美元預期。德康醫療當前全年的共識預期為每股收益 2.03 美元。Leerink Partnrs 還對德康醫療 2029 財年的收益預期為每股 4.41 美元。</p>
<p>德康醫療（NASDAQ:DXCM - 獲取免費報告）最近在 7 月 30 日星期三公佈了季度財報。該醫療設備公司報告季度每股收益（EPS）為 0.48 美元，超出市場共識預期的 0.45 美元，超出幅度為 0.03 美元。德康醫療的股本回報率為 32.05%，淨利潤率為 13.29%。該公司在本季度的收入為 11.6 億美元，而市場共識預期為 11.3 億美元。在去年同期，該公司每股收益為 0.43 美元。與去年同期相比，該公司的季度收入增長了 15.2%。</p>
<ul>
<li>3 只新 ETF 在投資者中獲得早期關注</li>
</ul>
<p>DXCM 的股票還受到其他幾份報告的關注。巴克萊將德康醫療的目標價從 93.00 美元上調至 98.00 美元，並在週三的報告中給予該股票 “持平” 評級。華爾街 Zen 在 7 月 18 日星期五將德康醫療的評級從 “持有” 上調至 “買入”。派珀·桑德勒在週四的報告中將德康醫療的目標價從 90.00 美元上調至 100.00 美元，並給予該股票 “超配” 評級。Truist Financial 在 6 月 16 日星期一開始對德康醫療進行覆蓋，給予 “買入” 評級和 102.00 美元的目標價。最後，瑞穗將德康醫療的目標價從 95.00 美元上調至 100.00 美元，並在 7 月 16 日的報告中給予該股票 “跑贏大盤” 評級。四位投資分析師對該股票給予 “持有” 評級，十六位給予 “買入” 評級，兩位給予 “強烈買入” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 99.89 美元。</p>
<p><strong>獲取我們對德康醫療的最新分析</strong></p>
<h2>德康醫療股票下跌 9.3%</h2>
<ul>
<li>關注的三隻股票：期權交易者押注大幅上漲</li>
</ul>
<p>德康醫療的股票在星期五開盤價為 80.77 美元。德康醫療的 1 年最低價為 57.52 美元，1 年最高價為 93.25 美元。該公司的 50 日移動平均線為 84.67 美元，200 日移動平均線為 80.62 美元。公司的市值為 316.7 億美元，市盈率為 56.09，市盈增長比率為 1.90，貝塔值為 1.44。公司的債務與股本比率為 0.55，流動比率為 1.50，速動比率為 1.32。</p>
<h2>機構資金流入和流出</h2>
<p>最近幾位大型投資者買入和賣出了 DXCM 的股票。Horizon Investments LLC 在第一季度增持了德康醫療的股份，增幅為 2.2%。Horizon Investments LLC 現在擁有德康醫療的 5608 股股票，價值 383,000 美元，在此期間又增持了 123 股。Nia Impact Advisors LLC 在第四季度增持了德康醫療的股份，增幅為 1.4%。Nia Impact Advisors LLC 現在擁有德康醫療的 9850 股股票，價值 766,000 美元，在此期間又增持了 140 股。Covestor Ltd 在第四季度增持了德康醫療的股份，增幅為 15.6%。Covestor Ltd 現在擁有德康醫療的 1109 股股票，價值 86,000 美元，在此期間又增持了 150 股。Wedbush Securities Inc.在第一季度增持了德康醫療的股份，增幅為 1.2%。Wedbush Securities Inc.現在擁有德康醫療的 13168 股股票，價值 899,000 美元，在上個季度又購買了 157 股。最後，Argonautica Private Wealth Management Inc.在第一季度增持了德康醫療的股份，增幅為 3.2%。Argonautica Private Wealth Management Inc.現在擁有德康醫療的 5958 股股票，價值 407,000 美元，在上個季度又購買了 182 股。97.75% 的股票由機構投資者和對沖基金持有。</p>
<h2>內部人員買賣</h2>
<p>在相關消息中，董事 Nicholas Augustinos 在 6 月 16 日星期一出售了 3672 股股票，交易價格為每股 82.80 美元，總交易額為 304,041.60 美元。交易完成後，該董事直接持有公司 33411 股股票，價值約為 2,766,430.80 美元。這代表其持股比例減少了 9.90%。該交易已在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。此外，執行副總裁 Michael Jon Brown 在 5 月 23 日星期五出售了 10,000 股股票，交易價格為每股 84.28 美元，總價值為 842,800.00 美元。交易完成後，該執行副總裁直接持有公司 95602 股股票，價值 8,057,336.56 美元。該交易代表其持股比例減少了 9.47%。該交易的披露信息可在此處找到。在過去三個月中，內部人員出售了 28656 股公司股票，價值 2,412,191 美元。當前公司內部人員持有的股票佔比為 0.32%。</p>
<h2>關於德康醫療</h2>
<p>（獲取免費報告）</p>
<p>德康醫療公司是一家醫療設備公司，專注於在美國及國際市場設計、開發和商業化連續血糖監測（CGM）系統。該公司為糖尿病患者及醫療服務提供者提供其系統。其產品包括 Dexcom G6 和 Dexcom G7，這些是用於糖尿病管理的集成 CGM 系統；Dexcom Share，一個遠程監測系統；Dexcom Real-Time API，允許授權的第三方軟件開發者將實時 CGM 數據集成到他們的數字健康應用和設備中；以及 Dexcom ONE，旨在替代指尖血糖測試以進行糖尿病治療決策。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過德康醫療</li>
<li>現在值得購買的 2 只金融科技股票和 1 只應避免的股票</li>
<li>Newmont 的財務實力為黃金礦業設定了高標準</li>
<li>投資旅遊股票的好處</li>
<li>黃金交叉警報：3 只具有重大上漲潛力的股票</li>
<li>成長股：它們是什麼，例子以及如何投資</li>
<li>大幅超預期，更大的計劃：AEP 股票因數據中心繁榮而上漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在德康醫療嗎？</h2>
<p>在你考慮德康醫療之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而德康醫療並不在名單上。</p>
<p>雖然德康醫療目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

德康醫療

<p>Leerink Partners 將 DexCom, Inc. 的 2028 財年每股收益（EPS）預期上調至 3.83 美元，較之前的 3.82 美元有所增加。目前全年每股收益的共識預期為 2.03 美元。DexCom 上個季度報告的每股收益為 0.48 美元，超出預期。分析師對 DexCom 的共識評級為 “適度買入”，目標價為 99.89 美元。該股票開盤價為 80.77 美元，市值為 316.7 億美元，市盈率為 56.09。機構投資者持有該股票的 97.75%</p>

<ul>
<li>DexCom Stock: Earnings Beat and New Market Access Drive Bull Case</li>
</ul>
<div class="lb-trans"><ul>
<li>德康醫療股票：財報超預期和新市場準入推動看漲預期</li>
</ul>
</div><p>DexCom, Inc. (NASDAQ:DXCM - Free Report) - Stock analysts at Leerink Partnrs raised their FY2028 earnings per share (EPS) estimates for DexCom in a report released on Wednesday, July 30th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will earn $3.83 per share for the year, up from their previous estimate of $3.82. The consensus estimate for DexCom's current full-year earnings is $2.03 per share. Leerink Partnrs also issued estimates for DexCom's FY2029 earnings at $4.41 EPS.</p>
<div class="lb-trans"><p>德康醫療公司（NASDAQ:DXCM - 免費報告）- 股票分析師在 7 月 30 日星期三發佈的報告中，上調了德康醫療 2028 財年的每股收益（EPS）預期。Leerink Partnrs 的分析師 M. Kratky 現在預計該醫療設備公司將實現每股收益 3.83 美元，高於之前的 3.82 美元預期。德康醫療當前全年的共識預期為每股收益 2.03 美元。Leerink Partnrs 還對德康醫療 2029 財年的收益預期為每股 4.41 美元。</p>
</div><p>DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 32.05% and a net margin of 13.29%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the company earned $0.43 earnings per share. The company's revenue for the quarter was up 15.2% compared to the same quarter last year.</p>
<div class="lb-trans"><p>德康醫療（NASDAQ:DXCM - 獲取免費報告）最近在 7 月 30 日星期三公佈了季度財報。該醫療設備公司報告季度每股收益（EPS）為 0.48 美元，超出市場共識預期的 0.45 美元，超出幅度為 0.03 美元。德康醫療的股本回報率為 32.05%，淨利潤率為 13.29%。該公司在本季度的收入為 11.6 億美元，而市場共識預期為 11.3 億美元。在去年同期，該公司每股收益為 0.43 美元。與去年同期相比，該公司的季度收入增長了 15.2%。</p>
</div><ul>
<li>3 New ETFs Finding Early Traction With Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只新 ETF 在投資者中獲得早期關注</li>
</ul>
</div><p>DXCM has been the subject of several other reports. Barclays increased their price target on DexCom from $93.00 to $98.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday. Wall Street Zen upgraded DexCom from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Friday, July 18th. Piper Sandler increased their price target on DexCom from $90.00 to $100.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday. Truist Financial started coverage on DexCom in a report on Monday, June 16th. They issued a &#34;buy&#34; rating and a $102.00 price target for the company. Finally, Mizuho increased their price target on DexCom from $95.00 to $100.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, July 16th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $99.89.</p>
<div class="lb-trans"><p>DXCM 的股票還受到其他幾份報告的關注。巴克萊將德康醫療的目標價從 93.00 美元上調至 98.00 美元，並在週三的報告中給予該股票 “持平” 評級。華爾街 Zen 在 7 月 18 日星期五將德康醫療的評級從 “持有” 上調至 “買入”。派珀·桑德勒在週四的報告中將德康醫療的目標價從 90.00 美元上調至 100.00 美元，並給予該股票 “超配” 評級。Truist Financial 在 6 月 16 日星期一開始對德康醫療進行覆蓋，給予 “買入” 評級和 102.00 美元的目標價。最後，瑞穗將德康醫療的目標價從 95.00 美元上調至 100.00 美元，並在 7 月 16 日的報告中給予該股票 “跑贏大盤” 評級。四位投資分析師對該股票給予 “持有” 評級，十六位給予 “買入” 評級，兩位給予 “強烈買入” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 99.89 美元。</p>
</div><p><strong>Get Our Latest Analysis on DexCom</strong></p>
<div class="lb-trans"><p><strong>獲取我們對德康醫療的最新分析</strong></p>
</div><h2>DexCom Stock Down 9.3%</h2>
<div class="lb-trans"><h2>德康醫療股票下跌 9.3%</h2>
</div><ul>
<li>Top 3 Stocks to Watch: Options Traders Bet on Big Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>關注的三隻股票：期權交易者押注大幅上漲</li>
</ul>
</div><p>Shares of DexCom stock opened at $80.77 on Friday. DexCom has a 1 year low of $57.52 and a 1 year high of $93.25. The business has a 50-day moving average of $84.67 and a two-hundred day moving average of $80.62. The company has a market capitalization of $31.67 billion, a P/E ratio of 56.09, a price-to-earnings-growth ratio of 1.90 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.</p>
<div class="lb-trans"><p>德康醫療的股票在星期五開盤價為 80.77 美元。德康醫療的 1 年最低價為 57.52 美元，1 年最高價為 93.25 美元。該公司的 50 日移動平均線為 84.67 美元，200 日移動平均線為 80.62 美元。公司的市值為 316.7 億美元，市盈率為 56.09，市盈增長比率為 1.90，貝塔值為 1.44。公司的債務與股本比率為 0.55，流動比率為 1.50，速動比率為 1.32。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several large investors have recently bought and sold shares of DXCM. Horizon Investments LLC boosted its stake in shares of DexCom by 2.2% during the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after acquiring an additional 123 shares during the period. Nia Impact Advisors LLC boosted its stake in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after acquiring an additional 140 shares during the period. Covestor Ltd boosted its stake in shares of DexCom by 15.6% during the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock worth $86,000 after acquiring an additional 150 shares during the period. Wedbush Securities Inc. lifted its holdings in DexCom by 1.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after purchasing an additional 157 shares during the last quarter. Finally, Argonautica Private Wealth Management Inc. lifted its holdings in DexCom by 3.2% during the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after purchasing an additional 182 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>最近幾位大型投資者買入和賣出了 DXCM 的股票。Horizon Investments LLC 在第一季度增持了德康醫療的股份，增幅為 2.2%。Horizon Investments LLC 現在擁有德康醫療的 5608 股股票，價值 383,000 美元，在此期間又增持了 123 股。Nia Impact Advisors LLC 在第四季度增持了德康醫療的股份，增幅為 1.4%。Nia Impact Advisors LLC 現在擁有德康醫療的 9850 股股票，價值 766,000 美元，在此期間又增持了 140 股。Covestor Ltd 在第四季度增持了德康醫療的股份，增幅為 15.6%。Covestor Ltd 現在擁有德康醫療的 1109 股股票，價值 86,000 美元，在此期間又增持了 150 股。Wedbush Securities Inc.在第一季度增持了德康醫療的股份，增幅為 1.2%。Wedbush Securities Inc.現在擁有德康醫療的 13168 股股票，價值 899,000 美元，在上個季度又購買了 157 股。最後，Argonautica Private Wealth Management Inc.在第一季度增持了德康醫療的股份，增幅為 3.2%。Argonautica Private Wealth Management Inc.現在擁有德康醫療的 5958 股股票，價值 407,000 美元，在上個季度又購買了 182 股。97.75% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人員買賣</h2>
</div><p>In related news, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director directly owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the transaction, the executive vice president directly owned 95,602 shares of the company's stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,656 shares of company stock valued at $2,412,191. 0.32% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Nicholas Augustinos 在 6 月 16 日星期一出售了 3672 股股票，交易價格為每股 82.80 美元，總交易額為 304,041.60 美元。交易完成後，該董事直接持有公司 33411 股股票，價值約為 2,766,430.80 美元。這代表其持股比例減少了 9.90%。該交易已在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。此外，執行副總裁 Michael Jon Brown 在 5 月 23 日星期五出售了 10,000 股股票，交易價格為每股 84.28 美元，總價值為 842,800.00 美元。交易完成後，該執行副總裁直接持有公司 95602 股股票，價值 8,057,336.56 美元。該交易代表其持股比例減少了 9.47%。該交易的披露信息可在此處找到。在過去三個月中，內部人員出售了 28656 股公司股票，價值 2,412,191 美元。當前公司內部人員持有的股票佔比為 0.32%。</p>
</div><h2>About DexCom</h2>
<div class="lb-trans"><h2>關於德康醫療</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.</p>
<div class="lb-trans"><p>德康醫療公司是一家醫療設備公司，專注於在美國及國際市場設計、開發和商業化連續血糖監測（CGM）系統。該公司為糖尿病患者及醫療服務提供者提供其系統。其產品包括 Dexcom G6 和 Dexcom G7，這些是用於糖尿病管理的集成 CGM 系統；Dexcom Share，一個遠程監測系統；Dexcom Real-Time API，允許授權的第三方軟件開發者將實時 CGM 數據集成到他們的數字健康應用和設備中；以及 Dexcom ONE，旨在替代指尖血糖測試以進行糖尿病治療決策。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than DexCom</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>Newmont's Financial Strength Sets a High Bar for Gold Miners</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Golden Cross Alert: 3 Stocks With Serious Upside Potential</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>Big Beat, Bigger Plans: AEP Stock Powers Up on Data Center Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過德康醫療</li>
<li>現在值得購買的 2 只金融科技股票和 1 只應避免的股票</li>
<li>Newmont 的財務實力為黃金礦業設定了高標準</li>
<li>投資旅遊股票的好處</li>
<li>黃金交叉警報：3 只具有重大上漲潛力的股票</li>
<li>成長股：它們是什麼，例子以及如何投資</li>
<li>大幅超預期，更大的計劃：AEP 股票因數據中心繁榮而上漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=DXCM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DexCom Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在德康醫療嗎？</h2>
</div><p>Before you consider DexCom, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮德康醫療之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而德康醫療並不在名單上。</p>
</div><p>While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然德康醫療目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Leerink Partners 對德康醫療 2028 財年收益的看法是積極的